BioNTech SE (ASX:BNTX)
110.685 USD
-0.795 0.713%Sponsored Reports
Previous Close (in USD) | 111.48 |
---|---|
Change | -0.795 0.713% |
52 W H/L (in USD) | 125.830/85.213 |
EBITDA (in USD) | -46.9M |
PE Ratio | 192.04 |
Volume | 433535 |
Diluted Eps TTM | 0.49 |
Total Assets (in USD) | 23006.3M |
---|---|
Total Liabilities (in USD) | 2760.4M |
Revenue TTM (in USD) | 2729.6M |
Cash (in USD) | 11663.7M |
Market Cap (in USD) | 22,677.158 M |
Revenue Per Share TTM | 11.369 |
Gross Profit TTM (in USD) | 16065.2M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
BioNTech SE
Employees: 6133
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Prof. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1965 |
2. | Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 |
3. | Prof. Christoph Hubert Huber M.D., Ph.D. | Co-Founder & Member of Supervisory Board | 1944 |
4. | Mr. Jens H. Holstein | CFO & Member of Management Board | 1963 |
5. | Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board | 1973 |
6. | Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | 1979 |
7. | Mr. Sean Marett | Chief Bus. Officer, Chief Commercial Officer & Member of Management Board | 1965 |
8. | Sylke Maas Ph.D. | VP of Investor Relations and Bus. Strategy | NA |
9. | Dr. James Timothy Patrick Ryan Ph.D. | Sr. VP & Gen. Counsel | NA |
10. | Michael Boehler | MD & Head of Global External Communications | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
NVO
Novo Nordisk A/S |
-1.880 1.680% | 110.19 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
NONOF
Novo Nordisk A/S |
+0.460 0.412% | 110 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
VRTX
Vertex Pharmaceuticals Inc |
+0.880 0.187% | 473.91 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
REGN
Regeneron Pharmaceuticals Inc |
-10.705 1.264% | 845.59 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Income Before Tax | 1186.1M | 12954.1M | 15046.4M | -145.802M | -179.44M |
Minority Interest | - | - | 0M | 0M | 0.116M |
Net Income | 930.3M | 9434.4M | 10292.5M | 15.2M | -179.172M |
Selling General Administrative | 495M | 484.7M | 278.5M | 94.049M | 40.692M |
Gross Profit | 3219.2M | 12778.6M | 15116M | -222.037M | -135.238M |
Reconciled Depreciation | 183.4M | 123.3M | 75.2M | 38.744M | 33.896M |
Ebit | 972M | 12642.7M | 15283.8M | -82.417M | -181.518M |
Ebitda | 1155.4M | 13096.3M | 14970.7M | -42.109M | -146.167M |
Depreciation And Amortization | 183.4M | 453.6M | -313.1M | 40.308M | 35.351M |
Operating Income | 690.4M | 12642.7M | 15283.8M | -82.417M | -181.518M |
Other Operating Expenses | 2914.8M | 4667.9M | 4060.8M | 564.742M | 290.107M |
Interest Expense | 7.738M | 18.9M | 5.4M | 64.949M | 1.718M |
Tax Provision | 255.8M | 3519.7M | 4753.9M | -161M | -0.268M |
Interest Income | 357.6M | 330.3M | 1.5M | 1.564M | 1.781M |
Net Interest Income | 349.7M | 311.4M | -25.8M | -3.487M | -0.263M |
Income Tax Expense | 255.8M | 3519.7M | 4753.9M | -161M | -0.268M |
Total Revenue | 3819M | 17310.6M | 18976.7M | 482.325M | 108.589M |
Total Operating Expenses | 2315M | 135.9M | 200.1M | -139.62M | 46.28M |
Cost Of Revenue | 599.8M | 4532M | 3860.7M | 704.362M | 243.827M |
Total Other Income Expense Net | -67.8M | 311.4M | -237.4M | -63.385M | 2.078M |
Net Income From Continuing Ops | 930.3M | 9434.4M | 10292.5M | 15.198M | -179.172M |
Net Income Applicable To Common Shares | - | - | 10292.5M | 15.198M | -179.056M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Total Assets | 23006.3M | 23279.1M | 15830.8M | 2318.62M | 797.647M |
Intangible Assets | 804.1M | 158.5M | 144.6M | 109.793M | 86.456M |
Other Current Assets | 280.9M | 271.9M | 64.9M | 60.966M | 1.182M |
Total Liab | 2760.4M | 3223.5M | 3937.1M | 946.774M | 304.155M |
Total Stockholder Equity | 20245.9M | 20055.6M | 11893.7M | 1371.846M | 493.492M |
Other Current Liab | 1335.1M | 2633.4M | 3002.6M | 103.05M | 16.439M |
Common Stock | 248.6M | 248.6M | 246.3M | 246.31M | 232.304M |
Capital Stock | 248.6M | 248.6M | 246.3M | 246.31M | 232.304M |
Retained Earnings | 19763.3M | 18833M | 9882.9M | -409.629M | -424.827M |
Good Will | 362.5M | 61.2M | 57.8M | 53.697M | 2.978M |
Other Assets | - | 249.2M | 22.2M | 168.231M | 2.403M |
Cash | 11663.7M | 13875.1M | 1692.7M | 1210.209M | 519.149M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 2070.5M | 2950.6M | 3481.6M | 606.014M | 138.142M |
Current Deferred Revenue | 353.3M | 77.1M | 189.1M | 391.534M | 93.583M |
Net Debt | -11444.6M | -13662.9M | -1391.2M | -970.02M | -450.245M |
Short Term Debt | 28.1M | 36M | 129.9M | 9.142M | 7.622M |
Short Long Term Debt | 28.1M | 36M | 129.9M | 9.142M | 0M |
Short Long Term Debt Total | 219.1M | 212.2M | 301.5M | 240.189M | 68.904M |
Other Stockholder Equity | 1218.6M | -5.3M | -3.8M | 1509.662M | -5.525M |
Property Plant Equipment | - | - | 520.4M | 325.956M | 148.062M |
Total Current Assets | 19527.3M | 21922M | 15072.3M | 1666.896M | 560.151M |
Long Term Investments | 1176.1M | 80.2M | 21.3M | - | 0M |
Short Term Investments | 4885.3M | 189.4M | 381.6M | 137.234M | 1.68M |
Net Receivables | 2339.7M | 7146M | 12382.1M | 166.366M | 20.205M |
Long Term Debt | 191M | 176.2M | 171.6M | 231.047M | 68.904M |
Inventory | 357.7M | 439.6M | 502.5M | 64.12M | 11.722M |
Accounts Payable | 354M | 204.1M | 160M | 102.288M | 20.498M |
Accumulated Other Comprehensive Income | -984.6M | 979.3M | 1768.3M | 25.503M | 691.54M |
Non Currrent Assets Other | 83.4M | 6.5M | 0.8M | 1.045M | 0.002M |
Non Current Assets Total | 3479M | 1357.1M | 758.5M | 651.724M | 237.496M |
Capital Lease Obligations | - | - | - | - | 0M |
Long Term Debt Total | - | - | - | - | 68.904M |
Cash Flow
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Investments | -6954.5M | -35.3M | -566.1M | -144.848M | -77.115M |
Total Cashflows From Investing Activities | - | - | -566.1M | -144.848M | -77.115M |
Total Cash From Financing Activities | -778.6M | -1419.3M | 94.2M | 894.725M | 383.29M |
Net Income | 1186.1M | 12954.1M | 15046.4M | -145.802M | -179.44M |
Change In Cash | -2211.4M | 12182.4M | 482.5M | 691.06M | 107.654M |
Begin Period Cash Flow | 13875.1M | 1692.7M | 1210.2M | 519.149M | 411.495M |
End Period Cash Flow | 11663.7M | 13875.1M | 1692.7M | 1210.209M | 519.149M |
Total Cash From Operating Activities | 5371.4M | 13577.4M | 889.7M | -13.474M | -198.537M |
Depreciation | 183.4M | 123.3M | 75.2M | 38.744M | 33.896M |
Other Cashflows From Investing Activities | - | - | - | - | -6.035M |
Dividends Paid | 0M | 484.3M | 0M | 0M | 0M |
Change To Inventory | 81.9M | 62.9M | -438.4M | -49.794M | -5.798M |
Sale Purchase Of Stock | -738.5M | -986.4M | 0M | 0M | 375.351M |
Other Cashflows From Financing Activities | 0.3M | 0.8M | -566.1M | 156.027M | 11M |
Capital Expenditures | 705.5M | 363.3M | 154M | 85.446M | 71.08M |
Change In Working Capital | 5574.8M | 4518.5M | -10730.4M | -93.097M | -83.436M |
Other Non Cash Items | -1275.5M | -4127.1M | 212.5M | 114.475M | 0.262M |
Free Cash Flow | 4665.9M | 13214.1M | 735.7M | -98.92M | -269.617M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Performer (AFRIS) | 8 months ago | 30261592 |
2. | Vanguard Capital Opportunity Inv | 7 months ago | 2357016 |
3. | AF High Growth (AFRIS) | 8 months ago | 2299505 |
4. | FvS SICAV Multiple Opportunities F | 9 months ago | 2120112 |
5. | Harding Loevner International Eq Instl | 7 months ago | 1855233 |
6. | iShares Biotechnology ETF | 6 months ago | 1532557 |
7. | PRIMECAP Odyssey Aggressive Growth | 7 months ago | 1362792 |
8. | Global Balanced (AFRIS) | 8 months ago | 1054891 |
9. | FvS Multiple Opportunities II I | 9 months ago | 1027264 |
10. | American Funds New Perspective A | 7 months ago | 799519 |
11. | Capital Group New Perspective Comp | 7 months ago | 799519 |
12. | Baillie Gifford WW L/T Glb Gr B USD Acc | 7 months ago | 650357 |
13. | PRIMECAP Odyssey Growth | 7 months ago | 437900 |
14. | Baillie Gifford L/T Glb Gr Invm B Acc | 7 months ago | 428986 |
15. | First Trust NYSE Arca Biotech ETF | 6 months ago | 426947 |
16. | Fidelity Contrafund | 7 months ago | 342586 |
17. | Harding Loevner International Equity K | 7 months ago | 341665 |
18. | Deka-GlobalChampions CF | 11 months ago | 340000 |
19. | AF Global Equity (AFRIS) | 8 months ago | 301666 |
20. | ACATIS Datini Valueflex Fonds A | 7 months ago | 280000 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Baillie Gifford & Co Limited. | 7 months ago | 8358939 |
2. | PRIMECAP Management Company | 7 months ago | 4807918 |
3. | Temasek Holdings Ltd. | 10 months ago | 4518080 |
4. | Harding Loevner L.P. | 10 months ago | 3944474 |
5. | Flossbach von Storch AG | 7 months ago | 3468986 |
6. | BlackRock Inc | 10 months ago | 1640016 |
7. | Capital World Investors | 7 months ago | 943116 |
8. | Altrinsic Global Advisors LLC | 7 months ago | 712708 |
9. | Quinn Opportunity Partners LLC | 10 months ago | 674583 |
10. | Morgan Stanley - Brokerage Accounts | 10 months ago | 628251 |
11. | Deutsche Bank AG | 10 months ago | 536853 |
12. | First Trust Advisors L.P. | 10 months ago | 416891 |
13. | DekaBank Deutsche Girozentrale | 7 months ago | 411897 |
14. | Goldman Sachs Group Inc | 10 months ago | 365756 |
15. | ClearBridge Advisors, LLC | 7 months ago | 361813 |
16. | Gilder Gagnon Howe & CO LLC | 10 months ago | 359708 |
17. | Squarepoint Ops LLC | 10 months ago | 316299 |
18. | Amundi | 10 months ago | 247016 |
19. | BAMCO Inc | 10 months ago | 242348 |
20. | Mitsubishi UFJ Trust & Banking Corp | 7 months ago | 216950 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).